Clinical trial registry record

Using direct observation of dying retinal cells technique to predict the likelihood of macular atrophy developing in newly diagnosed wet macular degeneration patients

A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered not applicable study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated January 14, 2026.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
ISRCTN22122298
Last registry update
January 14, 2026
Status
Recruiting
Phase
Not Applicable
Sponsor
Imperial College London
Enrollment
0
Countries
United Kingdom, England
Match confidence
100%
Source feed
ISRCTN Registry
Automated source synopsis

A registered Not Applicable study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Not Applicable
Study design
Observational
Evidence population
Human clinical study registration
Participants
0
Population
All · Mixed
Duration
2022-01-03 to 2027-12-31
Intervention
ANX776; Drug
Comparator
Not reported
Outcomes measured
1. Macular atrophy development measured using the DARC CNN score at baseline, 3 and 6 months 2. Presence of MA measured…; 1. Development of MA measured using OCT and FAF morphological biomarkers at 12 months 2. Prognostic value of CNN DARC s…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Not ApplicableA trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Abstract contains controlled term: age-related macular degeneration. Source terminology contains: age-related macular degeneration. Abstract supplies longevity context: age-related. Study type is explicitly identified as Observational.

Automated source check 98% · update recency 85%. These figures help sort records; they are not medical ratings.

vision aging
Open primary sourceExport JSON